Literature DB >> 16007630

Growth hormone benefits children with 18q deletions.

Jannine D Cody1, Margaret Semrud-Clikeman, L Jean Hardies, Jack Lancaster, Patricia D Ghidoni, Rebecca L Schaub, Nora M Thompson, Lynda Wells, John E Cornell, Tanzy M Love, Peter T Fox, Robin J Leach, Celia I Kaye, Daniel E Hale.   

Abstract

Most individuals with constitutional deletions of chromosome 18q have developmental delays, dysmyelination of the brain, and growth failure due to growth hormone deficiency. We monitored the effects of growth hormone treatment by evaluating 23 individuals for changes in growth, nonverbal intelligence quotient (nIQ), and quantitative brain MRI changes. Over an average of 37 months, the treated group of 13 children had an average nIQ increase of 17 points, an increase in height standard deviation score of 1.7, and significant change in T1 relaxation times in the caudate and frontal white matter. Cognitive changes of this magnitude are clinically significant and are anticipated to have an effect on the long-term outcomes for the treated individuals. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007630     DOI: 10.1002/ajmg.a.30848

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

1.  IV. Growth Failure in Institutionalized Children.

Authors:  Dana E Johnson; Megan R Gunnar
Journal:  Monogr Soc Res Child Dev       Date:  2011-12

2.  Growth and associations between auxology, caregiving environment, and cognition in socially deprived Romanian children randomized to foster vs ongoing institutional care.

Authors:  Dana E Johnson; Donald Guthrie; Anna T Smyke; Sebastian F Koga; Nathan A Fox; Charles H Zeanah; Charles A Nelson
Journal:  Arch Pediatr Adolesc Med       Date:  2010-04-05

3.  Growth patterns and the use of growth hormone in the mucopolysaccharidoses.

Authors:  L E Polgreen; B S Miller
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 4.  Comprehensive genetic testing approaches as the basis for personalized management of growth disturbances: current status and perspectives.

Authors:  Danielle Christine Maria van der Kaay; Anne Rochtus; Gerhard Binder; Ingo Kurth; Dirk Prawitt; Irène Netchine; Gudmundur Johannsson; Anita C S Hokken-Koelega; Miriam Elbracht; Thomas Eggermann
Journal:  Endocr Connect       Date:  2022-10-10       Impact factor: 3.221

5.  Deciphering short stature in children.

Authors:  Nella Polidori; Valeria Castorani; Angelika Mohn; Francesco Chiarelli
Journal:  Ann Pediatr Endocrinol Metab       Date:  2020-06-30

6.  18q22.1-qter deletion and 4p16.3 microduplication in a boy with speech delay and mental retardation: case report and review of the literature.

Authors:  Chunjing Wang; Huanhuan Ren; Huaifu Dong; Meng Liang; Qi Wu; Yaping Liao
Journal:  Mol Cytogenet       Date:  2018-10-19       Impact factor: 2.009

Review 7.  Clinical Characteristics and Long-Term Recombinant Human Growth Hormone Treatment of 18q- Syndrome: A Case Report and Literature Review.

Authors:  Shanshan Liu; Meiping Chen; Hongbo Yang; Shi Chen; Linjie Wang; Lian Duan; Huijuan Zhu; Hui Pan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.